Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials-Reference-Cited by-同舟云学术

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials

Published:2018-07-04 Issue:3 Volume:179 Page:615-622
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Blauvelt A.¹^ORCID,Reich K.²³^ORCID,Papp K.A.⁴^ORCID,Kimball A.B.⁵,Gooderham M.⁶⁷,Tyring S.K.⁸,Sinclair R.⁹,Thaçi D.¹⁰,Li Q.¹¹,Cichanowitz N.¹¹,Green S.¹¹,La Rosa C.¹¹

Affiliation:

1. Oregon Medical Research Center; 9495 SW Locust St, Suite G Portland OR 97223 U.S.A

2. Dermatologikum Berlin; Berlin Germany

3. ScIderm Research Institute; Hamburg Germany

4. K. Papp Clinical Research and Probity Medical Research; Waterloo ON Canada

5. Harvard Medical School; Boston MA U.S.A

6. SKiN Centre for Dermatology and Probity Medical Research; Peterborough ON Canada

7. Queens University; Kingston ON Canada

8. Department of Dermatology; University of Texas; Houston TX U.S.A

9. University of Melbourne; Melbourne Vic. Australia

10. University of Lübeck; Lübeck Germany

11. Merck & Co., Inc.; Kenilworth NJ U.S.A

Funder

Merck

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.16724/fullpdf

Reference27 articles.

1. Adalimumab therapy for moderate to severe psoriasis: a randomised, controlled phase III trial;Menter;J Am Acad Dermatol,2008

2. A global phase III randomised controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction;Papp;Br J Dermatol,2005

3. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial;Reich;Lancet,2005

4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial;Blauvelt;J Am Acad Dermatol,2017

5. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomised, double-blind, placebo-controlled trial;Krueger;J Allergy Clin Immunol,2015

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applications of Biological Therapy for Latent Infections: Benefits and Risks;International Journal of Molecular Sciences;2024-08-24

2. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

3. Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus;Journal of the European Academy of Dermatology and Venereology;2024-08-16

4. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer;BMJ Case Reports;2024-08

5. Low incidence of invasive fungal infections in a large observational cohort of patients initiating IL-17 or IL-23 inhibitor therapy, United States, 2016-2022;Journal of the American Academy of Dermatology;2024-07